Patient Risk group CD4/CD3 count (cells/µl) Viral load (copies/ml) NRTI NNRTI DRUGS AFFECTED
1 Blood transfusion 131/830 401,000 V75I A98V Potential low-level resistance: stavudine, didanosine.
2 Heterosexual 110/603 245,000 K219Q   Potential low-level resistance: stavudine, Low-level resistance: zidovudine.
3 Heterosexual 181/1005 29,600   V179D Potential low-level resistance: delavirdine, efavirenz, etravirine, nevirapine.
4 Heterosexual 176/1518 81,700   V179D Potential low-level resistance: delavirdine, efavirenz, etravirine, nevirapine
5 Heterosexual 59/853 1750,000   V179D Potential low-level resistance:delavirdine, efavirenz, etravirine, nevirapine
6 Heterosexual 50/265 1150,000   G190A Intermediate resistance:efavirenz, Low-level resistance:etravirine, High-level resistance:nevirapine
7 Heterosexual 510/3336 11,100   K103N High-level resistance:delavirdine, efavirenz, nevirapine, Potential low-level resistance:etravirine
8 Heterosexual 510/2822 92,200   G190V High-level resistance: efaviranz, nevirapine
Table 1: Showing drugs affected by mutations detected in eight of 122 HIV-positive ART naïve individual patients in RT-region of pol-gene.
Goto home»